New drug combo tested for rare blood cancer in japan
NCT ID NCT07340138
Summary
This small, early-stage study aims to check if adding a new drug called pelabresib to a standard medication (ruxolitinib) is safe for Japanese adults with myelofibrosis, a rare and serious bone marrow cancer. It will involve about 6 participants who are already taking a stable dose of ruxolitinib. The main goal is to monitor for any serious side effects while also gathering initial information on how the body processes the drug and if it helps reduce symptoms or spleen size.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PRIMARY MYELOFIBROSIS (PMF) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.